Paulo Teixeira has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Role Of Microbiome in Colorectal Cancer – A Systematic Review

    by Iara Santos, Diana Martins, Paulo Teixeira, Fernando Mendes

    INPLASY202570042 The Role Of Microbiome in Colorectal Cancer – A Systematic Review Keywords: Colorectal Neoplasms; Gastrointestinal Microbiome; Host Microbial Interactions; Drug Therapy. Read and d…

  • Open Access

    Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue

    by João Panão-Costa, Rui Caetano Oliveira, Paulo Teixeira, Francisco Caramelo, Maria Augusta Cipriano, Olga Borges, Armando Carvalho

    Chronic hepatitis B (CHB) remains a significant global health concern due to complications like cirrhosis and liver cancer. Immune cell exhaustion, characterized by increased suppressive molecules and inhibitory receptors, represents a critical feature of CHB. Understanding the mechanisms of hepatic immune exhaustion in CHB patients is imperative for the development of effective therapeutic interventions. In this study, we investigated the expression levels and histological distribution of various immune checkpoint receptors and ligands in liver biopsies obtained from CHB patients. Additionally, we aimed to evaluate potential concurrent overexpression of specific receptors and their association with clinical parameters such as ALT levels. Our analysis revealed that PD-1, PD-L1, CTLA-4, TIM-3, GAL-9, CD272, TIGIT, and 2B4 exhibited predominant localization in portal tracts and sinusoids. Furthermore, we observed a correlation between the expression of PD-1, TIM-3, and GAL-9 with ALT levels in CHB patients. Additionally, a strong relationship was identified between the expression of CD272 and TIGIT, as well as between GAL-9 and CTLA-4 within the studied population. Our findings underscore the significance of the TIM-3:GAL-9 pathway in the immunopathogenesis of CHB. This detailed analysis sets the stage for future combined immunotherapy strategies aimed at leveraging checkpoint receptors to enhance clinical outcomes.


  • Open Access

    177Lu-Trastuzumab Radionuclide Therapy: an Effective Approach for Resistant Brain Metastases in HER2+ Breast Cancer

    by Liliana Santos, Ivanna Hrynchak, José Sereno, Hugo Ferreira, Magda Silva, Rui Almeida, Paulo Teixeira, Antero Abrunhosa, Celia Gomes

    Purpose Breast cancer (BC) is the most common malignancy in women, with HER2 amplification present in 25–30% of metastatic cases. Although HER2-targeted therapies like trastuzumab have significantly improved patient outcomes, their efficacy in HER2 + brain metastases (BrM) is hindered by the emergence of resistance mechanisms. This study explores the therapeutic potential of trastuzumab radiolabeled with the β⁻-emitting radionuclide ¹⁷⁷Lu as a strategy to overcome resistance in HER2 + BrM. Material and methods HER2 + BC cell lines and their brain-tropic derivatives were assessed for HER2 expression and sensitivity to trastuzumab and [177Lu]Lu-DOTA-Trastuzumab. In vivo models were established by orthotopic implantation of HER2 + BC cells for primary tumor formation or intracardiac injection to induce BrM. Once tumors were established, the therapeutic efficacy of trastuzumab and [¹⁷⁷Lu]Lu-DOTA-Trastuzumab was evaluated by monitoring tumor progression via magnetic resonance imaging (MRI). [⁸⁹Zr]Zr-DFO-Trastuzumab PET imaging was performed to assess HER2 expression, while blood-brain barrier (BBB) permeability was evaluated using dynamic contrast-enhanced MRI. Results Brain-tropic HER2 + cells exhibited trastuzumab resistance despite maintaining HER2 expression. In contrast, [177Lu]Lu-DOTA-trastuzumab induced significant DNA damage and cytotoxicity. PET imaging confirmed specific radiotracer uptake in HER2 + primary tumors and BrM. A single dose of [177Lu]Lu-DOTA-trastuzumab effectively suppressed primary tumor growth and achieved complete BrM remission in 40% of treated animals. Heterogeneous BBB permeability was observed across metastatic lesions, potentially influencing radiotracer uptake and therapeutic efficacy. Conclusion These findings underscore [¹⁷⁷Lu]Lu-DOTA-trastuzumab as a novel therapeutic strategy to overcome trastuzumab resistance in HER2 + BrM, offering a promising approach to improve outcomes in metastatic BC.


  • Open Access

    ENPP1 induces blood–brain barrier dysfunction and promotes brain metastasis formation in human epidermal growth factor receptor 2-positive breast cancer

    by Liliana Santos, Francesca Tomatis, Hugo R S Ferreira, Sara F F Almeida, Edward Ciputra, José Sereno, Rui Almeida, Paulo Teixeira, Ana Sofia Ribeiro, João N Moreira, et al.

    Background: Brain metastasis (BrM) is a devastating end-stage neurological complication that occurs in up to 50% of human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients. Understanding how disseminating tumor cells manage to cross the blood–brain barrier (BBB) is essential for developing effective preventive strategies. We identified the ecto-nucleotidase ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) as specifically enriched in the secretome of HER2+ brain metastatic cells, prompting us to explore its impact on BBB dysfunction and BrM formation. Methods: We used in vitro BBB and in vivo premetastatic mouse models to evaluate the effect of tumor-secreted ENPP1 on brain vascular permeability. BBB integrity was analyzed by real-time fluorescence imaging of 20 kDa Cy7.5-dextran extravasation and immunofluorescence staining of adherens and tight junction proteins. Pro-metastatic effects of ENPP1 were evaluated in an experimental brain metastatic model. Results: Systemically secreted ENPP1 from primary breast tumors impaired the integrity of BBB with loss of tight and adherens junction proteins early before the onset of BrM. Mechanistically, ENPP1 induced endothelial cell dysfunction by impairing insulin signaling and its downstream AKT/GSK3β/β-catenin pathway. Genetic ablation of ENPP1 from HER2+ brain metastatic cells prevented endothelial cell dysfunction and reduced metastatic burden while prolonging the overall and metastasis-free survival of mice. Furthermore, plasmatic ENPP1 levels correlate with brain metastatic burden and inversely with overall survival. Conclusions: We demonstrated that metastatic BC cells exploit the ENPP1 signaling for cell transmigration across the BBB and brain colonization. Our data implicate ENPP1 as a potential biomarker for poor prognosis and early detection of BrM in HER2+ BC.


  • Open Access

    Clinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers

    by Rui Almeida, Carlos Abrantes, Davide Gigliano, Rui Caetano Oliveira, Paulo Teixeira, Marta Viegas, Ângelo Rodrigues, Maria José Julião

    Background: High-grade B-cell lymphoma (HGBL) with rearrangements of MYC and BCL2 and/or BCL6, called double and triple-hit lymphomas (DTH-HGBL), are lymphoid malignancies with inferior outcomes when treated with standard chemotherapy. The identification of DTH-HGBL cases is challenging, considering their variable clinical, morphologic, and immunohistochemical features. Materials and Methods: Retrospective revision of medical data of patients diagnosed with DTH-HGBL confirmed by FISH, between January 2010 and January 2020, in three Tertiary Portuguese Hospitals (Coimbra Hospital and University Center, Portuguese Oncology Institute – Coimbra and Portuguese Oncology Institute – Porto). Pathological features, morphology, and immunohistochemical profile were evaluated by at least two experienced pathologists in hematopoietic and lymphoid neoplasms. Results: The cohort included 24 patients: 33.3% triple-hit, 58.3%, MYC/BCL2 double-hit and 8.3% MYC/BCL6 double-hit. There was no gender predominance, with a median age of 62.5±14.3y, 33.3% were diagnosed as nodal disease, and 66.7% as extranodal. Morphologic features of DLBCL were present in 50% of cases, morphological features of both DLBCL and Burkitt lymphoma (DLBCL/BL) in 45.8% and 4.2% of blastoid morphology. Immunohistochemical evaluation, regarding the Hans algorithm, revealed a Germinal center (GC)/GC-like subtype in 83.3% of cases and a non-GC/non-GC-like subtype in 16.7%. MYC was positive in 42.9% and the median proliferative index was 80±12.4%. Conclusion: DTH-HGBL has a very broad range of features. We consider that a cost-effective approach would be to perform cytogenetic analysis in DLBCL and DLBCL/BL cases with GC/GC-like subtype. MYC and BCL2 immunohistochemistry can be useful to identify patients who may benefit from more aggressive therapies, but not as tools for case selection for FISH.


  • Open Access

    Histological scores and tumor size on stage II in adrenocortical carcinomas

    by Rui Caetano Oliveira, Maria João Martins, Carolina Moreno, Rui Almeida, João Carvalho, Paulo Teixeira, Miguel Teixeira, Edgar Tavares Silva, Isabel Paiva, Arnaldo Figueiredo, et al.

    Adrenocortical carcinomas (ACC) are aggressive tumors with a poor prognosis. Histological scores are advised for the diagnosis, however, there are borderline cases that may be misjudged as adrenocortical adenomas (ACA). The three main scores used are: Weiss Modified System (WMS), Reticulin Algorithm (RA), and Helsinki Score (HS). We intend to compare the accuracy of the three scores in ACC diagnosis and to identify predictive factors of overall survival (OS). Retrospective study (2004–2016) at Centro Hospitalar e Universitário de Coimbra of the adrenal tumors, classified as ACC or ACA, with a history of posterior tumor relapse/metastases, without lesions in the contralateral adrenal gland: 13F and 6M, with a median age of 51 ± 12.41 years. Nodules’ median size was 9.20 ± 6.2 cm. Patients had a median OS of 52 ± 18.6 months, with 57.9% and 46.3%, at 3 and 5 years. Seven patients had local recurrence and nine had metastases. Thirteen cases were in stage II. The WMS and the HS allowed a diagnosis of ACC in 15 cases and the RA defined ACC in 17 cases. All cases had, at least, focal disruption of the reticulin framework. More than 5 mitosis/50 HPF was associated with worse OS: 49.67 ± 21.43 versus 108.86 ± 14.02 months (p = 0.026). In patients with stage II, tumor size ⩾10 cm was associated with worse OS: 19.25 ± 7.15 versus 96.11 ± 16.7 months (p = 0.007), confirmed by multivariate analysis (p = 0.031). The correct diagnosis of ACC is a pathologist responsibility. The RA seems the most accurate. Any loss of the reticulin framework should raise awareness for malignancy. In patients on stage II, a size ⩾10 cm is a predictor of worse prognosis.


  • Open Access

    Prognostic Factors After Hepatectomy for Gastric Adenocarcinoma Liver Metastases: Desmoplastic Growth Pattern as the Key to Improved Overall Survival

    by Maria José Temido, Rui Caetano Oliveira, Ricardo Martins, Marco Serôdio, Beatriz Costa, César Carvalho, Eva Santos, Luís Ferreira, Paulo Teixeira, Maria Augusta Cipriano, et al.

    Purpose: Hepatectomy (Hp) is an alternative approach for the treatment of gastric carcinoma liver metastases (GCLM). However, prognostic factors that may assist patient selection are still controversial. Several pathologic features, such as the growth pattern (GP), associated with prognosis in colorectal cancer liver metastases, were never investigated in GCLM. Our principal aim was to assess if the GP has prognostic impact on GCLM. Patients and Methods: Review of the clinical and pathological characteristics of 19 consecutive patients submitted to surgical resection of GCLM with curative intent at our department. Major potential prognostic factors considered were patients’ gender, age, timing and extent of Hp, postoperative course, as well as histopathological characteristics of primary and secondary tumors. Results: Major morbidity occurred in four patients, mortality in one. Median and 5-year overall survival were 17 months and 26.7%, respectively. Ten patients developed recurrent disease and two patients survived more than 10 years. Factors independently associated with overall survival were the absence of major morbidity, distal location of the primary tumor, and desmoplastic GP (p< 0.05). Conclusion: The selection of patients is crucial for the improvement of survival rates of GCLM. Consequently, we demonstrate for the first time that the desmoplastic GP of GCLM is associated with improved outcomes, prompting further research on tumor–host interactions.


  • Open Access

    De novo colorectal cancer after liver and kidney transplantation–Microenvironment disturbance

    by Rui Caetano Oliveira, Edgar Tavares-Silva, Ana Margarida Abrantes, Hugo Antunes, Paulo Teixeira, Ana Gomes, Ricardo Martins, Emanuel Furtado, Arnaldo Figueiredo, Beatriz Costa, et al.


  • Morphophenotypic Classification of Hepatocellular Carcinoma: the Biliary/Stem Cell Subgroup and Worst Outcome—Implications on Patient Selection

    by Rui Caetano Oliveira, Ricardo Martins, Ana Margarida Abrantes, Ângela Jesus, Paulo Teixeira, Carolina Canhoto, Pedro Guerreiro, Beatriz Costa, Mário Rui Silva, José Guilherme Tralhão, et al.


  • Open Access

    Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine

    by Barbora Tesarova, Simona Dostalova, Veronika Smidova, Zita Goliasova, Zuzana Skubalova, Hana Michalkova, David Hynek, Petr Michalek, Hana Polanska, Marketa Vaculovicova, et al.